Trial Profile

A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary) ; Sintilimab (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms Orient-11
Sponsors Innovent Biologics

11 May 2026 Actual primary completion date changed from 13 Feb 2023 to 15 Nov 2019.
12 Sep 2023 Results of Post hoc analyses predicting development of severe immune-related adverse events during treatment of ICIs , presented at the 24th World Conference on Lung Cancer
12 Sep 2023 Results presented at the 24th World Conference on Lung Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com